<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532727</url>
  </required_header>
  <id_info>
    <org_study_id>ICR-CTSU/2006/10003</org_study_id>
    <secondary_id>ISRCTN97330959</secondary_id>
    <secondary_id>Main REC: 07/Q0603/67</secondary_id>
    <secondary_id>CTA: 22138/0004/001-0001</secondary_id>
    <secondary_id>EudraCT Number: 2006-004470-26</secondary_id>
    <nct_id>NCT00532727</nct_id>
  </id_info>
  <brief_title>Triple Negative Breast Cancer Trial</brief_title>
  <acronym>TNT</acronym>
  <official_title>Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breakthrough Breast Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is greater activity for carboplatin
      than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer.
      The trial aims to recruit between 370 and 450 patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations.</measure>
    <time_frame>Time from start of treatment to 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression</measure>
    <time_frame>Time from start of treatment until confirmation of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression or death.</measure>
    <time_frame>Time from start of treatment until confirmation of progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure: this will be defined as time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease as defined by RECIST</measure>
    <time_frame>Time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival: this will be defined as time from randomisation until death from any cause in the intention to treat population</measure>
    <time_frame>Time from randomisation until death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity will be assessed throughout the treatment period using the National Cancer Institute Common Terminology Criteria for Adverse Events version three (NCI CTCAE v3.0)</measure>
    <time_frame>Time from start of treatment to 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6 every 3 weeks for six cycles (18 weeks)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>100mg/m2 every 3 weeks for six cycles (18 weeks)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed ER-, PR-, primary breast cancer

          -  Histologically confirmed HER2- primary breast cancer

          -  Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for
             local therapy but suitable for taxane chemotherapy

          -  Patients with stable, treated bain metastases will be eligible providing informed
             consent can be given and that other sites of measurable disease are present.

          -  Patients with bone metastases currently receiving bisphosphonates for palliation will
             be eligible providing informed consent can be given and that other sites of measurable
             disease are present

          -  ECOG Performance Status 0, 1, or 2

          -  Adequate haematology, biochemical indices (FBC, U &amp; Es)

          -  LFTs = Normal bilirubin, AST and/or ALT = 3 x ULN if Alk Phos &gt;5 x ULN (or an isolated
             elevation AST/ALT of â‰¤5 x ULN

          -  Adequate renal function - Creatinine clearance of &gt;25mls per minute

          -  Written informed consent, able to comply with treatment and follow up

        Exclusion Criteria:

          -  Original primary tumour or subsequent relapse known to be positive for any of ER, PR,
             or HER2 receptors

          -  Patients unfit for chemotherapy or those with neuropathy &gt;grade 1 (sensory or motor)

          -  Known allergy to platinum compounds or to mannitol

          -  Known sensitivity to taxanes

          -  Patients with inoperable locally advanced disease suitable for local radiotherapy or
             an anthracycline containing regimen

          -  Previous chemotherapy for metastatic disease other than an anthracycline as in
             inclusion criteria above

          -  Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry

          -  Previous treatment with a taxane for recurrent locally advanced disease

          -  Previous treatment with a platinum chemotherapy drug

          -  LFTs = Abnormal bilirubin (&gt; ULN), AST and/or ALT &gt;3 X ULN and Alk Phos &gt;5 x ULN (or
             an isolated elevation AST/ALT of &gt;5 x ULN)

          -  Patients with a life expectancy of less than 3 months

          -  Previous malignancies other than adequately treated in situ carcinoma of the uterine
             cervix or basal or squamous call carcinoma of the skin, unless there has been a
             disease free interval of at least 10 years

          -  Previous or synchronous second breast cancer (unless also confirmed ER-, PR- and
             HER2-)

          -  Patients with bone limited disease

          -  Other serious uncontrolled medical conditions or concurrent medical illness likely to
             compromise life expectancy and/or the completion of trial therapy

          -  Pregnant, lactating or potentially childbearing women not using adequate contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Tutt, MB ChB, MRCP, FRCR, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Triple Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

